Scott Gottlieb Quotations

This approval is another example of our agency's endeavor to counter rising healthcare costs by approving safe and effective generic alternatives as soon as the law permits.

You are unlikely to see our science-based approach change just because of shifts in the public discourse.

We are going to initiate a public process for trying to gather information for what additional guidelines we could issue to make sure that these ads are providing truthful and non-misleading information.

But as generic drugs continue to play an increasingly prominent role in the health of Americans, we need to also continue to make sure that the generic drug program remains on stable financial footing.

The aim of all these initiatives is to prevent drug manufacturing from creating a bottleneck in getting medicines to patients.

There is a disconnect between the investment we're making in discovering treatments and the result in practical treatments that are reaching patients. We think that there are scientific approaches we could be taking that would help us learn more about drugs in a shorter time and for less cost.

We must do more than ever to monitor the performance of (device) products after they are approved, and make sure that we are quickly discovering and sharing information about problems that do arise.

We think that if your company complies with the FDA processes, if you bring forward the benefits and risks of your drug, and let your information be judged through a process with highly trained scientists, you should not be second-guessed by state courts that don't have the same scientific knowledge.

Maybe we're not being overly cautious but instead trying to be responsive.